Latest news with #Gaucher
Global News
2 days ago
- Business
- Global News
Community rallies around Calgary business owner following break-in
Over the past six years, Laura Gaucher has turned her lifestyle into her career as owner of vintage western wear store Good Gals Vintage. 'I tried to commit to the bit, I guess,' Gaucher laughed. 'I knew if I wanted to do this full-time I had to commit my full-time hours. Starting her business just before the pandemic, Gaucher's already seen highs and lows. Earlier this week, she was dealt one of the latter. After styling a photoshoot for another local business — Routine Natural Beauty — Gaucher's vehicle was broken into. Vintage jackets, bolo ties, shorts, pants and more than a dozen cowboy hats — a collection that included some of Gaucher's personal items — were gone. Story continues below advertisement 'It feels a little crazy… they took like 15 to 20 cowboy hats. I don't know how they were walking away with that — but it's gone,' she said. She estimates the items were worth between $3,000 and $5,000. Making matters worse, it comes at the beginning of summer — Gaucher's busiest time of year. 'The biggest thing for me is the cowboy hats, the belts and the bolo ties. They're such a seller during Calgary Stampede. Everybody wants a cowboy hat. Everybody wants to wear a western belt to make their outfit a little more western.' Get daily National news Get the day's top news, political, economic, and current affairs headlines, delivered to your inbox once a day. Sign up for daily National newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy While Gaucher says she still has lots of other items safe and sound, it represents a blow to her stock when she has very limited time to recoup what's lost. 'I think any vintage dealer will tell you that we're never not sourcing, for sure, but it's definitely the most depleting this time,' she said. 'I have Stampede stuff and then I … have a booth at Calgary Folk Fest and some other festivals and stuff like that. So July is definitely my busiest season where I don't necessarily have time to replenish.' In the wake of the unfortunate news, Alberta's small business and arts community is stepping up to help one of their own. Story continues below advertisement 'It's great having Laura here… she brings her own eclectic flair and obviously some of the coolest style around,' said Andrew Bullied, founder of Annex Ales. The Calgary brewery and taproom has started a donation drive in hopes of giving Laura a hand. 'Come on by, have a beer… if you've got some nice vintage western wear, any donation will help. Laura needs to rebuild her business ahead of her busiest time.' Bullied said. Lauren Gillis met Gaucher while Gillis was touring with an Alberta country artist, and Gaucher was selling clothes at pop-up shops along the way. 'Her and I were road-dogging it together,' laughed Gillis, who also goes by her stage name, Lucette. 'I also did vintage markets way back in the day so she had me at a couple of her markets and we got close over the music world.' Gillis says she's seen Gaucher's business grow over the years, often intertwined with the Alberta music scene. In times like this, she says it's only natural the community Gaucher has served helps her out. 'Within the music and vintage selling community, everyone is on the same team,' Gillis said. Story continues below advertisement Gaucher is still holding out hope some of the precious items might pop up at local pawn shops or online. She says she's still relatively stocked up and excited for the busy season ahead, including a market at Thomson Family Park from June 20-22. But even in the span of a few days, the outpouring of support has helped to turn things around.
Time of India
01-06-2025
- Health
- Time of India
Rare disease patients continue to struggle despite govt policies
New Delhi: Despite the establishment of the National Policy for Rare Diseases (NPRD) in 2021 and a nationwide financial assistance programme, over 300 patients, predominantly children diagnosed with Lysosomal Storage Disorders (LSDs) such as Gaucher, Pompe, Fabry, MPS I, and II, are left without essential medical care. Tired of too many ads? go ad free now Among them, 70 are from Delhi. Since 2022, nearly 50 patients—including six from Delhi—have succumbed to these diseases. The Lysosomal Storage Disorders Support Society (LSDSS) reports that 50 patients across India exhausted their one-time funding under the policy. In Delhi, 7 patients are in critical condition due to financial constraints. Alishba Khan, a young girl battling Gaucher disease, illustrates the dire consequences of limited funding. Her father, Maqsood Alam, recounts the devastating decline in her health following the discontinuation of her medication in Aug 2024. "She suffers from severe abdominal pain, an enlarged spleen, bone pain, weakness, and decreased haemoglobin level. She is unable to attend school and requires constant supervision," Alam shared, his voice filled with anguish. Having already lost four children, he continually appeals to the High Court for continued treatment, fearing for Alishba's survival. While doctors at AIIMS offer significant support, they are constrained by limited funding, he said. Recognising the critical need, the Delhi High Court on Oct 4, 2024, directed the Ministry of Health and Family Welfare to extend funding beyond the Rs 50 lakh cap for patients with rare diseases. The court also mandated the establishment of a Rs 974 crore national fund for rare diseases for the fiscal years 2024-25 and 2025-26. Tired of too many ads? go ad free now However, the Ministry challenged this directive in the Supreme Court, where the matter remains pending. The Lysosomal Storage Disorders Support Society (LSDSS) has been vigorously campaigning for urgent action. In a recent appeal to Union Health Minister JP Nadda, the LSDSS highlighted that despite allocating over Rs 205 crore to 12 Centres of Excellence (CoEs)—including AIIMS Delhi and MAMC—more than 300 eligible patients remain untreated, and at least 50 patients have died while awaiting treatment. LSDSS National President Manjit Singh emphasised that many of these patients are children with conditions for which DCGI-approved therapies exist. " In the Budget Session of Parliament, the Ministry reaffirmed that no eligible patient should be denied life-saving therapy. However, the disconnect between funding and actual treatment on the ground continues to undermine this commitment," the letter stated. The society requested the ministry to direct CoEs to immediately accept eligible patients, ensure compliance with NPRD 2021 guidelines, prioritise patients with approved therapies, establish a rapid response task force for timely treatment initiation, and authorise continued treatment support beyond the Rs 50 lakh cap based on clinical merit. Singh acknowledged the govt's historic support for rare disease patients, requesting leadership to ensure this support translates into timely, life-saving access. Officials at MAMC explained that the crowdfunding portal has technical constraints preventing status updates from 'waiting for treatment' to 'under treatment' after therapy begins. Although the portal displays zero patients receiving treatment, in reality, 10 individuals out of 28 registered cases of LSDs are currently undergoing enzyme replacement therapy (ERT). The administration confirmed that treatment allocation strictly follows approved eligibility standards, considering ERT's expected clinical effectiveness and requires approval from the Centre of Excellence (CoE) committee, comprising various medical specialists. They noted that patients with significant neurological symptoms receive lower priority, as current evidence suggests ERT offers minimal benefits in such instances. The focus remains on treating patients with a higher likelihood of substantial clinical benefits. Regarding the national policy's one-time financial support limit of Rs 50 lakh per patient, the MAMC officials indicated their inability to provide treatment beyond this amount without specific instructions from senior authorities. When contacted, Dr Neerja Gupta from the genetic unit of paediatrics at AIIMS said she doesn't have the details on this matter offhand.
Yahoo
29-05-2025
- Business
- Yahoo
Cerezyme Market Research Report 2025: Epidemiology, Pipeline Analysis, Insights & Forecasts 2019-2024, 2024-2029F, 2034F
Explore our in-depth Cerezyme market report, analyzing growth, segmentation, and competitive landscape. Discover trends driving increased adoption, including gene therapy and R&D investments. North America leads, with Asia-Pacific as the fastest-growing region. Ideal for Gaucher disease treatment insights. Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Cerezyme Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to offering. The Cerezyme market report offers an extensive analysis of key characteristics, such as market size, growth potential, and segmentation. It presents a regional and country-wise market breakdown, showcasing both historical data and future growth projections. Competitive landscape, market share insights, emerging trends, and strategic developments are thoroughly examined to provide a comprehensive overview of the sector. Historical market growth has been driven by increased global healthcare expenditure, the rise of clinical trials, adoption of personalized medicine, use of electronic health records, and growth in medical tourism. Looking ahead, growth is expected due to the rising prevalence of rare diseases, heightened demand for enzyme replacement therapies, an increase in genetic disorders, gene therapy advances, and burgeoning biotech investments. Key upcoming trends include technological advancements, the further personalization of medicine, artificial intelligence integration, and the use of combination therapies. Investment in research and development (R&D) is pivotal to the Cerezyme market's growth. R&D facilitates the creation and enhancement of enzyme replacement therapies, aiming to boost treatment effectiveness, improve patient outcomes, and address unmet needs for Gaucher disease treatment. The rise in R&D expenditure is propelled by demand for innovation and technological progress, illustrated by the UK pharmaceutical sector's significant R&D investment in 2022. Expansion in healthcare infrastructure is anticipated to bolster the Cerezyme market. With advancements driven by population growth, increased healthcare demands, and technological improvements, healthcare systems worldwide are expanding. Enhanced infrastructure supports effective administration of enzyme replacement therapy, as exemplified by the increase in U.S. hospitals from 2022 to 2024. Such expansion is crucial for market progress. A notable trend is the expansion of manufacturing facilities to meet rising global demand. Specialized biologics manufacturing plants utilize advanced technologies to produce high-quality drugs, ensuring scalable production and regulatory compliance. Sanofi S.A.'s new Singapore manufacturing facility, a response to increased demand, exemplifies this trend, showcasing an investment aimed at elevating production capacity. Sanofi S.A. remains a key player in the Cerezyme market. Geographically, North America led in 2024, with Asia-Pacific poised as the fastest-growing region. The report encompasses regions such as Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa, and includes countries like Australia, Brazil, China, France, Germany, India, and others. Cerezyme, an enzyme replacement therapy, is essential for treating Gaucher disease. It alleviates symptoms by replacing deficient enzymes, preventing fatty substance accumulation in organs. The main indications for Cerezyme include Gaucher's disease Types 1 and 3. Distribution channels span direct sales, pharmaceutical wholesalers, online, and retail pharmacies, catering to hospitals, clinics, ambulatory care centers, and home care settings. The Cerezyme market comprises sales of infusion equipment, gene therapy products, and supportive care medications. The market's value represents enterprise revenues through goods/services sales within specified markets and geographies, excluding supply chain resales. This report provides an expansive view of the Cerezyme market, equipping stakeholders with vital data for future industry navigation. Key Topics Covered: 1. Executive Summary 2. Cerezyme Market Characteristics 3. Cerezyme Market Biologic Drug Characteristics 3.1. Molecule Type 3.2. Route of Administration (ROA) 3.3. Mechanism of Action (MOA) 3.4. Safety and Efficacy 4. Cerezyme Market Trends and Strategies 5. Cerezyme Market - Macro Economic Scenario 6. Global Cerezyme Growth Analysis and Strategic Analysis Framework 6.1. Global Cerezyme PESTEL Analysis 6.2. Analysis of End Use Industries 6.3. Global Cerezyme Market Growth Rate Analysis 6.4. Global Cerezyme Historic Market Size and Growth 6.5. Global Cerezyme Forecast Market Size and Growth 6.6. Global Cerezyme Total Addressable Market (TAM) 7. Global Cerezyme Pricing Analysis & Forecasts 8. Cerezyme Market Segmentation 8.1. Global Cerezyme Market, Segmentation by Indication 8.2. Global Cerezyme Market, Segmentation by Distribution Channel 8.3. Global Cerezyme Market, Segmentation by End Use 9. Global Cerezyme Epidemiology of Clinical Indications 9.1. Drug Side Effects 9.2. Incidence and Prevalence of Clinical Indications 10. Cerezyme Market Regional and Country Analysis 10.1. Global Cerezyme Market, Split by Region 10.2. Global Cerezyme Market, Split by Country For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-05-2025
- Business
- Yahoo
WuXi Biologics Congratulates Partner CANbridge Pharmaceuticals on the Approval of Innovative Velaglucerase-beta for Injection (Gaurunning) for Gaucher Disease by China NMPA
Enabled by WuXi Biologics' industry-leading integrated technology platform, velaglucerase-beta for injection has successfully advanced from concept to commercialization. Velaglucerase-beta for injection, as the first and the only locally developed enzyme replacement therapy (ERT) for Gaucher disease in China, marks a significant breakthrough for CANbridge Pharmaceuticals and WuXi Biologics in advancing R&D of innovative rare disease therapeutics in China. Velaglucerase-beta for injection is the first innovative biological product in China to pass segmented manufacturing inspection. WUXI, China and SHANGHAI, May 16, 2025 /PRNewswire/ -- WuXi Biologics ( a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its partner CANbridge Pharmaceuticals on the approval of its innovative velaglucerase-beta for injection (Gaurunning) by the China National Medical Products Administration (NMPA) for the treatment of adolescents aged 12 and above and adults with type I and type III Gaucher disease. This marks China's first and only locally developed enzyme replacement therapy (ERT) for Gaucher disease. Gaucher disease is a rare inherited genetic lysosomal storage disorder characterized by clinical manifestations such as hepatosplenomegaly, anemia, bone pain, and neurological symptoms, which can be life-threatening in severe cases. Recombinant human glucocerebrosidase ERT has been the standard treatment for Gaucher disease for 30 years, significantly improving major non-neurological signs and symptoms, as well as improving the quality of life for patients. It is estimated that the global prevalence of Gaucher disease is 0.7 to 1.75 per 100,000 people. Gaucher disease has been included in China's "First List of Rare Diseases". Velaglucerase-beta for injection is the first collaboration project on rare diseases between CANbridge and WuXi Biologics, advancing from concept to commercialization by leveraging WuXi Biologics' leading integrated technology platform. The project utilized innovative technology to construct high-expression cell line and achieved significant improvements in both yield and quality through WuXiUPTM, an ultra-high productivity continuous bioprocessing platform of WuXi Biologics. The overall yield increased by more than 110 times, and the specific enzyme activity increased by more than 50%, ensuring the affordability for Gaucher disease patients. Additionally, WuXi Biologics developed cell-based bioassay methods for commercial product release and stability testing, addressing the technical challenges of enzyme testing and effectively ensuring product quality control. Additionally, velaglucerase-beta for injection is the first innovative biological product in China to pass segmented manufacturing inspection. Dr. Chris Chen, CEO of WuXi Biologics, stated, "We are honored to enable CANbridge to achieve the significant milestone of approval for velaglucerase-beta for injection, which represents a critical advancement in rare disease drug innovation in China. Developing therapies for rare diseases is a long and challenging journey, requiring relentless joint efforts to bridge the gap between early-stage discovery and patients' access to medication. The successful commercialization of velaglucerase-beta for injection not only reflects CANbridge's decade-long dedication to rare diseases but also exemplifies the value of WuXi Biologics' integrated platform and CRDMO business model. Furthermore, our shared commitment to addressing the unmet clinical needs of rare disease patients has resulted in China's first locally developed ERT for Gaucher disease. We look forward to enabling more global partners to accelerate the development of high-quality rare disease therapies, and making them accessible and affordable for more patients suffering from rare diseases." Dr. James Xue, Founder, Chairman, and CEO of CANbridge Pharmaceuticals, stated, "Enzyme replacement therapy is a crucial part of CANbridge' global pipeline. The approval of velaglucerase-beta for injection in China is a milestone. By leveraging the integrated technology platform, velaglucerase-beta for injection will significantly reduce development costs, making safe and effective domestically produced ERT accessible and affordable for patients. This product is also the first collaboration project between CANbridge and WuXi Biologics in rare diseases. We extend our gratitude to our partners, including WuXi Biologics, who have empowered the development and manufacturing of velaglucerase-beta for injection. This milestone is not only CANbridge' third rare disease drug to be launched following Hunterase® and Livmarli®, but also the first in-house developed commercialized product. In the future, we will continue to focus on the localized research, manufacturing, commercialization, and accessibility of rare disease drugs, bringing innovative treatments to patients in China." Since its establishment, WuXi Biologics has been committed to enabling global innovative biotech companies to accelerate the rare disease drugs from concept to commercialization, benefiting rare disease patients worldwide. As ofthe end of 2024, there are 21 rare disease projects on the company's platform. Additionally, the company actively promotes public awareness and supports the rare disease patient community through various philanthropic initiatives. Its global "Run for Health" campaign has engaged over 2,500 participants to raise awareness for rare diseases. In China, the company's "Rare Disease Student Education Support Program" has provided scholarships to over 100 students affected by rare diseases over the past four years, fostering their academic growth. About Velaglucerase-beta for Injection (Gaurunning) Velaglucerase-beta for injection is the first domestically developed recombinant human glucocerebrosidase ERT in China, now approved for clinical use in treatment of Type I and Type III Gaucher disease patients. Most Gaucher disease patients are Type I and Type III, which are chronic non-neuronopathic and chronic neuronopathic forms, respectively. velaglucerase-beta is administered as an intravenous infusion and is intended to supplement the lack of glucocerebrosidase in the lysosomes of GD patients. The pivotal clinical trial of velaglucerase-beta achieved positive top-line data in August 2024. The velaglucerase-beta pivotal trial is a randomized, double-blind, dose-comparison study designed to evaluate the efficacy, safety, and pharmacokinetics of intravenous velaglucerase-beta administered every other week in newly treated Gaucher Disease (GD) patients, with an extension period. The results demonstrate that the study successfully met its primary efficacy endpoint, showing a statistically significant mean percentage reduction from baseline in spleen volume at nine months for both the 60 U/kg dose (P<0.0001) and the lower 30 U/kg dose (P<0.001). The primary endpoint of this trial protocol has been agreed upon by the CDE. About Gaucher Disease (GD) Gaucher disease, one of the most common lysosomal storage disorders, is a rare inherited genetic metabolic disease caused by autosomal recessive mutations in the GBA gene located on chromosome 1q22 and affects both males and females equally. Gaucher disease is a clinical spectrum that comprises Type 0 (perinatal-lethal), Type I (chronic non-neuronopathic), Type II (acute neuronopathic), and Type III (chronic neuronopathic) forms, with Types I and III surviving into adulthood. Gaucher disease is caused by a deficiency of glucocerebrosidase (acid b-glucosidase), an enzyme that helps break down a cellular membrane glycosphingolipid called glucocerebroside (glucosylceramide) inside lysosomes. As a result, glucocerebroside accumulates primarily in cells of the monocyte-macrophage lineage (Gaucher cells) within certain organs, leading to splenomegaly, hepatomegaly, anemia, thrombocytopenia, bone pain and fractures, and in the most severe forms (perinatal-lethal, Types II and III), early neurological symptoms. For 30 years, recombinant human glucocerebrosidase enzyme replacement therapy (ERT) has been the standard of care for Gaucher disease, with clinical trials and real-world data demonstrating significant improvement in the major non-neurological signs and symptoms of disease and quality of life. There were 3,000 patients with Gaucher disease in China in 2020, according to Frost & Sullivan. Gaucher disease has been included in China's "First List of Rare Diseases." About WuXi Biologics WuXi Biologics (stock code: is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide. With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects). WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain. For more information about WuXi Biologics, please visit: About Canbridge CANbridge Pharmaceuticals Inc. (HKEX:1228) is a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies for rare disease. CANbridge has a differentiated drug portfolio, with 3 approved drugs and a pipeline of 8 assets, targeting prevalent rare disease indications that have unmet needs and significant market potential. These include Hunter syndrome and other lysosomal storage disorders, complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases. The CANbridge Next-Generation Innovation and Process Development Facility is developing novel, potentially curative, gene therapies for rare genetic diseases, including Pompe disease, Fabry disease, spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD) and other neuromuscular conditions, and collaborates with world-leading researchers and biotech companies. CANbridge global partners include: Apogenix, GC Pharma, Mirum, Wuxi Biologics, Privus, UMass Chan Medical School, the University of Washington School of Medicine and Scriptr Global. For more on CANbridge Pharmaceuticals Inc., please go to: Contacts Businessinfo@ MediaPR@ View original content: SOURCE WuXi Biologics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-05-2025
- Business
- Yahoo
Sharp Therapeutics Corp. Nominates Clinical Candidate for Gaucher's Disease
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - May 13, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical-stage biotechnology company developing small molecule therapies to treat genetic diseases, announces that it has nominated a small molecule compound from its GBA program for clinical development in Gaucher's disease. Sharp has launched its clinical development program for Gaucher's disease by nominating a compound from the SEL-148,721 series of GBA1-restoring small molecules to enter IND-enabling studies. The company plans to begin compound scale-up and formal safety studies during the second half of 2025. If successful, the Company expects to file an IND application with the Food and Drug Administration and enter Phase I clinical trials in 2026. About the SHRX Gaucher's Program. Sharp discovered the SEL-148,172 series by applying its Disco™ discovery platform to identify compounds that enhance mutant GBA functional activity. Gaucher's disease is caused by mutation(s) in the GBA enzyme that reduce enzymatic function leading to disease. The candidate compound restores enzymatic activity, which has been shown to be an effective means of treating Gaucher's. Current Gaucher's treatments include recombinant replacement enzyme therapies, which require regular infusions with some patients developing allergic resistance to therapy. Sharp's candidate compound is an orally-available small molecule making it much more convenient for patients, and much more efficient to produce and distribute reliably. "This is the first program from our platform to enter FDA-reportable studies and is a milestone for Sharp as it transitions to a clinical stage company," said Scott Sneddon, CEO/CSO of Sharp. "The compounds show robust activity in animal models, and more importantly, in cells taken from Gaucher's patients containing several of the most common GBA mutations," he added. "These compounds are also brain penetrant, leaving the prospect for treating CNS manifestations of Gaucher's, a market not effectively treated by existing therapies." The scientific data supporting the compounds will be presented at the GBA1 Conference in Montreal starting June 5, 2025 of which Sharp is also a meeting sponsor. About Sharp Therapeutics Corp. - First-Choice Therapies for Genetic Diseases Sharp Therapeutics is a pre-clinical stage company developing first-choice small-molecule therapeutics for hereditary disorders. The Company's discovery platform combines novel high throughput screening technologies, with compound libraries computational optimized based on the physics and biology of cellular trafficking defects and allosteric activation of proteins. The platform produces small molecule compounds that restore activity in mutated proteins giving the potential to treat genetic disorders with conventional pill-based medicines. For additional information on Sharp, please visit: Sharp Therapeutics Sneddon, PhD, JDCEO/CSOEmail: scott@ Caution Regarding Forward-Looking Information Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect Sharp's current views and intentions with respect to future events, and current information available to Sharp, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Should any factor affect Sharp in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Sharp does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and Sharp undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit Sign in to access your portfolio
